Amgen Inc. Files SEC Form 4 Report

According to a recent SEC filing, Amgen Inc. disclosed a significant update related to the company's leadership and corporate structure. The filing, submitted on March 8, 2023, provides insight into the company's compliance with US securities regulations. As a major biopharmaceutical company, Amgen Inc. is subject to strict reporting requirements, including the disclosure of executive compensation and ownership information.

Key Takeaways:

• The SEC filing, Form 4, was submitted by Amgen Inc. on March 8, 2023, and discloses changes in the company's leadership and corporate structure.
• The filing is required under Section 12 of the Securities Exchange Act of 1934, which mandates public companies to submit statements of ownership regarding equity securities.
• The Form 4 filing provides information on the reporting person's relationship to the company and on purchases and sales of equity securities.
• This filing is a formal document submitted to the SEC by publicly-traded companies, like Amgen Inc., to ensure compliance with US securities regulations.
• The filing is available on the SEC website, with the filing ID of 0001127602-23-009503.
• The contact information for Amgen Inc., listed in the filing, is One Amgen Center Drive, Thousand Oaks, CA 91320, with a phone number of (805)447-1000.

Statistics:

• Date of SEC filing: March 8, 2023
• SIC code for Amgen Inc.: 2836, Biological Products
• SEC filing ID: 0001127602-23-009503
• Contact information for Amgen Inc.: One Amgen Center Drive, Thousand Oaks, CA 91320, (805)447-1000

Sources:

• Amgen Inc. SEC Form 4 filing (https://www.sec.gov/Archives/edgar/data/1365306/0001127602-23-009503-index.html)
• U.S. Securities and Exchange Commission (SEC) website (https://www.sec.gov)